Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lundbeck's Alzheimer's Strategy Targets Symptoms And Disease Modification

Executive Summary

The private company may be behind the leaders, but with a long-term plan and a strategy of coming in with complementary therapies like the 5-HT6 receptor antagonist idalopirdine and the dopamine antagonist Rexulti (brexpiprazole), it could be a stable player in Alzheimer's.

You may also be interested in...



Otsuka/Lundbeck Closer To Adding Alzheimer’s Agitation To Rexulti Label

With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.

Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?

Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.

Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test

Lundbeck’s 5-HT6 antagonist idalopirdine failed its first Phase III test, but as Axovant awaits data from its Phase III study for a competing Alzheimer’s therapy, it’s still unclear whether the entire drug class is doomed to the same fate.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel